Senators criticize iPLEDGE
Executive Summary
A bipartisan group of senators, including Dick Durbin (D-Ill.), Judd Gregg (R-N.H.) and Orrin Hatch (R-Utah), are calling on FDA to fix the iPLEDGE risk management plan covering Roche's Accutane and isotretinoin generics. In a letter to FDA, the senators express concern that the program increases the risks of therapy by unnecessarily causing extended use. The group also complains that iPLEDGE has caused some physicians to stop prescribing the drug. The risk management plan went into effect March 1 (1"The Pink Sheet" Feb. 20, 2006, p. 14)...